Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MEN1 | O00255 | 4/20 | 0.55 |
| ▸ | KMT2A | Q03164 | 4/20 | 0.55 |
| ▸ | ANO1 | Q5XXA6 | 10/20 | 0.53 |
| ▸ | HPGD | P15428 | 2/20 | 0.50 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.50 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.50 |
| ▸ | MAPT | P10636 | 2/20 | 0.49 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.48 |
| ▸ | LMNA | P02545 | 2/20 | 0.48 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.46 |
| ▸ | TNF | P01375 | 1/20 | 0.46 |
| ▸ | NOD1 | Q9Y239 | 1/20 | 0.46 |
| ▸ | SMO | Q99835 | 1/20 | 0.46 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL12756894 | 0.91 | MEN1 (0.65) | MEN1KMT2AANO1HPGDCYP1A2 | |
| SCHEMBL12831006 | 0.91 | MEN1 (0.53) | MEN1KMT2AANO1HPGDCYP1A2 | |
| SCHEMBL12756898 | 0.88 | MEN1 (0.53) | MEN1KMT2AANO1MAPTLMNA | |
| SCHEMBL12756892 | 0.88 | ANO1 (0.46) | MEN1KMT2AANO1HPGDMAPT | |
| SCHEMBL12756545 | 0.86 | ANO1 (0.49) | MEN1KMT2AANO1HPGDMAPT | |
| SCHEMBL1490458 | 0.84 | ANO1 (0.55) | ANO1 | |
| SCHEMBL12756890 | 0.84 | PPARG (0.56) | MEN1KMT2AANO1MAPT | |
| SCHEMBL1490373 | 0.84 | KMT2A (0.52) | MEN1KMT2AANO1HPGDMAPT | |
| SCHEMBL1490509 | 0.83 | KMT2A (0.55) | MEN1KMT2AANO1HPGDMAPT | |
| SCHEMBL12756773 | 0.83 | MEN1 (0.52) | MEN1KMT2AHPGDCYP1A2CYP2C19 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20140051711-A1 | COMPOUNDS THAT MODULATE INTRACELLULAR CALCIUM | CALCIMEDICA INC. (US) | 2014-02-20 | — | — | US | disclosed |
| WO-2011034962-A2 | COMPOUNDS THAT MODULATE INTRACELLULAR CALCIUM | CALCIMEDICA INC. (US) | 2011-03-24 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20140051711-A1 | COMPOUNDS THAT MODULATE INTRACELLULAR CALCIUM | ORAI1, SARAF, RYR2 | MEN1 2958/4885KMT2A 4706/4885ANO1 114/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.